Do you want to read an article? Please log in or register.
Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy
Inflammatory Bowel Disease
Related content
COMMENTED
Inflammatory Bowel Disease
Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy
★ 3
Recommended and commented by
PD Dr Luc Biedermann, Faculty Member
★ 3
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Aliment Pharmacol Ther.
Kopylov U, Hanzel J, Liefferinckx C, De Marco D, Imperatore N, Plevris N, Baston-Rey I, Harris RJ, Truyens M, Domislovic V, Vavricka S, Biemans V, Myers S, Sebastian S, Ben-Horin S, González Lama Y, Gilletta C, Ariella BS, Zelinkova Z, Weishof R, Storan D, Zittan E, Farkas K, Molnar T, Franchimont D, Cremer A, Afif W, Castiglione F, Lees C, Barreiro-de Acosta M, Lobaton T, Doherty G, Krznaric Z, Pierik M, Hoentjen F, Drobne D
doi: 10.1111/apt.15784.
Inflammatory Bowel Disease
Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study
Lancet Gastroenterol Hepatol.
Feagan BG, Sandborn WJ, Danese S, Wolf DC, Liu WJ, Hua SY, Minton N, Olson A, D'Haens G
doi: 10.1016/S2468-1253(20)30188-6.
Inflammatory Bowel Disease
Early Transmural Response Assessed Using Magnetic Resonance Imaging Could Predict Sustained Clinical Remission and Prevent Bowel Damage in Patients with Crohn's Disease Treated with Anti-Tumour Necrosis Factor Therapy
J Crohns Colitis.
Messadeg L, Hordonneau C, Bouguen G, Goutorbe F, Reimund JM, Goutte M, Boucher AL, Scanzi J, Reymond M, Allimant C, Dapoigny M, Pereira B, Bommelaer G, Buisson A
doi: 10.1093/ecco-jcc/jjaa098.
Inflammatory Bowel Disease
Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical Remission
Clin Gastroenterol Hepatol.
Hanžel J, Zdovc J, Kurent T, Sever N, Javornik K, Tuta K, Koželj M, Smrekar N, Novak G, Štabuc B, Dreesen E, Thomas D, Vovk T, Grabnar I, Drobne D
doi: 10.1016/j.cgh.2020.02.033.
Inflammatory Bowel Disease
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
Lancet Gastroenterol Hepatol.
Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, Thomas A, Nice R, Perry MH, Bouri S, Chanchlani N, Heerasing NM, Hendy P, Lin S, Gaya DR, Cummings JRF, Selinger CP, Lees CW, Hart AL, Parkes M, Sebastian S, Mansfield JC, Irving PM, Lindsay J, Russell RK, McDonald TJ, McGovern D, Goodhand JR, Ahmad T; UK Inflammatory Bowel Disease Pharmacogenetics Study Group
doi: 10.1016/S2468-1253(19)30012-3.
Inflammatory Bowel Disease
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients with Crohn's Disease
Gastroenterology.
Adedokun OJ, Xu Z, Gasink C, Jacobstein D, Szapary P, Johanns J, Gao LL, Davis HM, Hanauer S, Feagan BG, Ghosh S, Sandborn WJ
doi: 10.1053/
Inflammatory Bowel Disease
Metabonomics and the gut microbiome associated with primary response to anti-TNF therapy in Crohn's disease
J Crohns Colitis.
Ding NS, McDonald JAK, Perdones-Montero A, Rees DN, Adegbola SO, Misra R, Hendy P, Penez L, Marchesi JR, Holmes E, Sarafian MH, Hart AL
doi: 10.1093/ecco-jcc/jjaa039.
Inflammatory Bowel Disease
Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn's Disease: A Post Hoc Analysis of GEMINI 2 and 3
Inflamm Bowel Dis.
Sands BE, Van Assche G, Tudor D, Akhundova-Unadkat G, Curtis RI, Tan T
doi: 10.1093/ibd/izy384.
Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study
Lancet Gastroenterol Hepatol.
Feagan BG, Panés J, Ferrante M, Kaser A, D'Haens GR, Sandborn WJ, Louis E, Neurath MF, Franchimont D, Dewit O, Seidler U, Kim KJ, Selinger C, Padula SJ, Herichova I, Robinson AM, Wallace K, Zhao J, Minocha M, Othman AA, Soaita A, Visvanathan S, Hall DB, Böcher WO
doi: 10.1016/S2468-1253